Oppenheimer upgrades AutoZone — NewEdge Wealth CEO Rob Sechan owns it and breaks it down, while the Investment Committee drops their latest picks.
HistoSonics, a medical technology company backed by Johnson & Johnson , is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing peopl
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK a
24/7 Wall St. Key Points: Warren Buffett’s investment philosophy emphasizes long-term holdings in companies with strong competitive moats, such as Coca-Cola (NYSE: KO), American Express (NYSE: A

US FDA approves J&J's immune disorder drug

08:41am, Wednesday, 30'th Apr 2025
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday.
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older   IMAAVY delivered rapid and substantial reduction in immunoglobu
CEOs and other executives from Nvidia , Johnson & Johnson , Toyota Motor , Eli Lilly and SoftBank Group are among the more than two-dozen senior business leaders slated to visit the White House on Wed
I present 10 must-own dividend stocks for your retirement portfolio to help you blend dividend income, growth and capital appreciation, designed to anchor a well-diversified dividend portfolio. Allian
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein's 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate
In a market where investors are increasingly seeking stability and reliable returns, several industry giants have stepped up with significant dividend increases. Johnson & Johnson NYSE: JNJ, Costco W
Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manuf
First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients av
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR Results reinforce potential
Phase 2b SunRISe-1 study shows more than 82 percent of patients achieved complete response (CR) with more than half of responders remaining cancer-free at one year after CR1
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, altho
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE